Compare · Research-Use-Only

Ipamorelin vs Ipamorelin / CJC-1295

Ipamorelin alone produces a selective GH pulse without meaningfully elevating cortisol or prolactin. The Ipamorelin / CJC-1295 combination pairs that pulse with CJC-1295's extended half-life for sustained GH and IGF-1 elevation in research protocols.

Spec

Ipamorelin

Ipamorelin / CJC-1295

Class

Synthetic peptide

Molecular weight

711.85 Da

711.85 Da (ipamorelin) / 3367.97 Da (CJC-1295 no-DAC)

Sequence

Aib-His-D-2Nal-D-Phe-Lys-NH2

Aib-His-D-2Nal-D-Phe-Lys-NH2 (ipamorelin); Modified GHRH(1-29) (CJC-1295)

Purity

>=99%

Form

Lyophilized powder

CAS number

170851-70-4

170851-70-4 (ipamorelin)

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue pentapeptide, a five-amino-acid chain that prompts the pituitary to release its own growth hormone. It acts as a partial agonist at the ghrelin receptor (GHS-R1a), stimulating pulsatile GH release from pituitary somatotrophs. Unlike older GH secretagogues, ipamorelin is highly selective, with minimal effects on ACTH, cortisol, aldosterone, or prolactin.

View Ipamorelin Buy Ipamorelin

Ipamorelin / CJC-1295

This combination targets two distinct but synergistic nodes in the growth hormone (GH) axis. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH(1–29)) carrying four amino acid substitutions that make it resistant to the enzyme DPP-4, which extends its half-life. The non-DAC version (also known as mod-GRF(1–29)) has a half-life of ~30 minutes. The DAC (Drug Affinity Complex) version binds covalently to plasma albumin through a maleimide linker, giving it a half-life of approximately 6–8 days and allowing once or twice-weekly dosing. CJC-1295 acts on the GHRH receptor (GHRHR) on pituitary somatotrophs, the pituitary cells that release GH, and increases the size of each GH pulse. Ipamorelin is a selective growth hormone secretagogue pentapeptide. It acts as a partial agonist at the ghrelin receptor (GHS-R1a) and increases how often GH pulses occur, working through a different intracellular pathway (Gq/PKC rather than Gs/cAMP). Ipamorelin is also highly selective for that receptor: at research doses it does not appreciably stimulate ACTH, cortisol, or aldosterone release, unlike older GH secretagogues (GHRP-6, GHRP-2). Giving CJC-1295 (pulse size) and ipamorelin (pulse frequency) together produces GH release patterns that more closely mimic youthful physiological pulsatility. In preclinical and small human studies, the pair raised GH and IGF-1 more than either agent alone.

View Ipamorelin / CJC-1295 Buy Ipamorelin / CJC-1295